This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Carlo Alberto Tassinari, MD; Roberto Michelucci, MD; Giovanni Ambrosetto, MD; Fabrizio Salvi, MD

Arch Neurol. 1987;44(9):907-910.

Abstract
• Thirty-one patients with severe drugresistant epilepsy entered the study. Vigabatrin (2 to 3 g/d, stratified according to weight) and placebo were administered orally, as add-on therapy in random order under double-blind conditions, each for three months using a crossover design. Thirty patients completed both periods. Of these, ten patients (33%) showed a decrease in seizure frequency of 50% or more. In the 15 patients presenting with complex partial seizures, "temporal" electroencephalographic abnormalities, and relatively low seizure frequency, there was a significant reduction in seizure frequency during vigabatrin treatment. No significant treatment effect was found for the remaining 15 patients, who presented with mixed seizure types, multifocal electroencephalographic abnormalities, and high seizure frequencies. Tolerability to vigabatrin was good; the most frequently reported unwanted effect was drowsiness. Plasma concentrations of phenytoin showed a significant reduction during the vigabatrin period. The results demonstrate the efficacy and good tolerability of vigabatrin therapy in patients with severe complex partial epilepsy.

Author Affiliations
From the Neurological Clinic, University of Bologna (Italy) School of Medicine.

Footnotes
Accepted for publication March 30, 1987.

Read before the 16th Epilepsy International Congress, Hamburg, Germany, Sept 8, 1985.

Reprint requests to Neurological Clinic, University of Bologna School of Medicine, Via Ugo Foscolo n.7, 40123 Bologna, Italy (Dr Tassinari).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Recent Advances in the Treatment of Epilepsy
Nguyen and Spencer
Arch Neurol 2003;60:929-935.
FULL TEXT  

Use of Topiramate in Childhood Generalized Seizure Disorders
Wheless
J Child Neurol 2000;15:S7-S13.
ABSTRACT  

Quality of life measures in epilepsy: How well can they detect change over time?
Birbeck et al.
Neurology 2000;54:1822-1827.
ABSTRACT | FULL TEXT  

Optimizing the Indication of Vigabatrin in Children With Refractory Epilepsy
Lortie et al.
J Child Neurol 1997;12:253-259.
ABSTRACT  

Sequential Neuropathology of Dogs Treated with Vigabatrin, a GABA-Transaminase Inhibitor
Yarrington et al.
Toxicol Pathol 1993;21:480-489.
ABSTRACT  

Long-term Antiepileptic Efficacy of Vigabatrin in Drug-Refractory Epilepsy in Mentally Retarded Patients: A 5-Year Follow-up Study
Pitkanen et al.
Arch Neurol 1993;50:24-29.
ABSTRACT  

Effect of Long-Term Vigabatrin Therapy on Selected Neurotransmitter Concentrations in Cerebrospinal Fluid
Ben-Menachem et al.
J Child Neurol 1991;6:2S11-2S16.
ABSTRACT  

Neuropathologic Findings in Patients Receiving Long-Term Vigabatrin Therapy for Chronic Intractable Epilepsy
Cannon et al.
J Child Neurol 1991;6:2S17-2S24.
ABSTRACT  

Vigabatrin in Refractory Epilepsy in Adults and Its Application in Children
Dam
J Child Neurol 1991;6:2S25-2S29.
ABSTRACT  

Vigabatrin in Childhood Epilepsy
Dulac et al.
J Child Neurol 1991;6:2S30-2S37.
ABSTRACT  

Vigabatrin in Pediatric Epilepsy--An Open Study
Uldall et al.
J Child Neurol 1991;6:2S38-2S44.
ABSTRACT  

Dose-Response Study of Vigabatrin in Children With Refractory Epilepsy
Herranz et al.
J Child Neurol 1991;6:2S45-2S51.
ABSTRACT  

Chronic Toxicity Studies with Vigabatrin, A GABA-Transaminase Inhibitor
Gibson et al.
Toxicol Pathol 1990;18:225-238.
ABSTRACT